Can a lung drug stop COVID scarring?

NCT ID NCT04619680

First seen May 07, 2026 · Last updated Jun 06, 2026 · Updated 3 times

Summary

This study tested whether nintedanib, a drug used for other lung diseases, can slow down lung damage in people who had severe COVID-19. It included 103 adults who still had lung problems more than 30 days after their COVID diagnosis. The main goal was to see if the drug helped maintain lung function over 6 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

  • Baylor University Medical Center Dallas

    Dallas, Texas, 75246, United States

  • Emory Healthcare Network

    Atlanta, Georgia, 30322, United States

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Mount Sinai Beth Israel

    New York, New York, 10003, United States

  • The Johns Hopkins Hospital

    Baltimore, Maryland, 21287, United States

  • University of Utah

    Salt Lake City, Utah, 84108, United States

Conditions

Explore the condition pages connected to this study.